Abraxane plus gemcitabine was superior to gemcitabine alone with statistically significant and clinically meaningful results across primary and key secondary endpoints and patient subgroups Oral ...

First new treatment to be approved for pancreatic cancer in nearly seven years, highlighting the challenges and unmet needs in treating the disease BOUDRY, Switzerland--(BUSINESS WIRE)--Jan. 7, 2014-- ...

Please provide your email address to receive an email when new articles are posted on . The randomized phase 3 APACT trial was a well-designed adjuvant trial that evaluated the addition of ...

Top-line results announced from the international Phase 3 study evaluating adjuvant therapy with ABRAXANE in combination with gemcitabine vs. gemcitabine alone for patients with surgically resected ...

NICE does not deem Abraxane more effective than FOLFIRINOX, in addition to the fact that it causes severe side effects. The National Institute for Health and Care Excellence has published new ...

The SWOG 1815 trial showed that adding nab-paclitaxel (Abraxane) to gemcitabine and cisplatin did not improve progression-free (PFS) or overall survival (OS) but did increase toxicity. The ...

Today we finally heard the data from the much-awaited abstract, examining gemcitabine, cisplatin, and Abraxane as compared to gemcitabine and cisplatin in first-line biliary tract cancers. This was ...

Shortly after the Food and Drug Administration approved a combination using it with the first-ever immunotherapy drug to win the agency’s nod for breast cancer, a Celgene chemotherapy agent has failed ...

Diagnostic value of Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) for the diagnosis of hepatocellular carcinoma in cirrhotic patients. Background: G is ...

DATE and TIME: (US PT) 11:30am - 1:00pm, Friday, January 9 th, 2026 LOCATION: Level 1, West Hall, Moscone West, Poster K5 Amplia Therapeutics Limited is an Australian pharmaceutical company advancing ...

ABRAXANE plus gemcitabine also demonstrated a statistically significant improvement in key secondary endpoints compared to gemcitabine alone, including a 31% reduction in the risk of progression or ...